Research graph
References from Large esophageal varices predict hepatocellular carcinoma in newly diagnosed cirrhosis: insights from machine learning and propensity score analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Molecular pathophysiology of portal hypertension
10.1002/hep.27343 · 2015 · External reference
Endothelial dysfunction in the regulation of cirrhosis and portal hypertension
10.1111/j.1478-3231.2011.02579.x · 2012 · External reference
IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study
10.1186/s12876-015-0283-5 · 2015 · External reference
The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age, and sex: a Swedish nationwide population-based cohort study
10.1002/ueg2.12238 · 2022 · External reference
Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies
10.1038/s41598-023-30467-5 · 2023 · External reference
Hepatocellular carcinoma incidence in alcohol-associated cirrhosis: systematic review and meta-analysis
10.1016/j.cgh.2022.06.032 · 2023 · External reference
The neoangiogenic transcriptomic signature impacts hepatocellular carcinoma prognosis and can be triggered by transarterial chemoembolization treatment
10.3390/cancers16203549 · 2024 · External reference
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis
10.1016/j.jhep.2022.01.023 · 2022 · External reference
A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions
2024 · External reference
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease
10.1053/j.gastro.2008.09.014 · 2009 · External reference
Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naive patients with chronic hepatitis B-related compensated cirrhosis in Taiwan
10.1111/apt.16116 · 2020 · External reference
Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis
10.1053/jhep.2003.50093 · 2003 · External reference
Friend or Foe? Spontaneous Portosystemic Shunts in Cirrhosis-Current Understanding and Future Prospects
10.1155/2021/8795115 · 2021 · External reference
Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension
10.1016/j.jhep.2015.05.022 · 2015 · External reference
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma
10.1016/j.jhep.2018.03.019 · 2018 · External reference
Constructing inverse probability weights for marginal structural models
10.1093/aje/kwn164 · 2008 · External reference
The central role of the propensity score in observational studies for causal effects
10.1093/biomet/70.1.41 · 1983 · External reference
Random survival forests
10.1214/08-aoas169 · 2008 · External reference
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis
10.1016/j.jhep.2009.01.014 · 2009 · External reference
Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study
10.3390/v16091439 · 2024 · External reference
Non-invasive assessment of portal hypertension: Liver stiffness and beyond
2024 · External reference
Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma
10.1111/apt.17599 · 2023 · External reference
Meta-analysis: accuracy of the Baveno VI criteria for the diagnosis of high-risk varices in patients with hepatocellular carcinoma
10.3389/fonc.2024.1482290 · 2024 · External reference
DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C
2024 · External reference
Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals
10.1002/hep.29911 · 2018 · External reference
The pathophysiology of portal hypertension
10.1016/j.cld.2024.03.001 · 2024 · External reference
Liver injury and regeneration: current understanding, new approaches, and future perspectives
10.3390/cells12172129 · 2023 · External reference
Flow-dependent shear stress affects the biological properties of pericyte-like cells isolated from human dental pulp
10.1186/s13287-023-03254-2 · 2023 · External reference
Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis
10.1371/journal.pone.0200855 · 2018 · External reference
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis
10.1053/j.gastro.2012.07.018 · 2012 · External reference
Hypoxia-induced ANGPTL4 sustains tumour growth and anoikis resistance through different mechanisms in scirrhous gastric cancer cell lines
10.1038/s41598-017-11769-x · 2017 · External reference
Angpt2/Tie2 autostimulatory loop controls tumorigenesis
10.15252/emmm.202114364 · 2022 · External reference
Organ fibrosis: emerging diagnostic and therapeutic strategies
10.1016/j.mam.2024.101259 · 2024 · External reference
